TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Intramyocardial Injection of Autologous Human Mesenchymal Stem Cells (MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction (MI) Undergoing Cardiac Surgery for Coronary Artery Bypass Grafting (CABG)
Brief Summary: Heart attacks are a leading cause of death in both men and women in the United States. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly, that area of the heart can suffer permanent damage. While recovery from a heart attack can be managed through medications and lifestyle changes, these treatments can not reverse the original damage to the heart. Current research is focusing on the development of cell-based therapies using stem cells to repair organs that have been irreversibly damaged by disease. A specific form of stem cells, called adult mesenchymal stem cells (MSCs), has shown promise for heart repair. This study will evaluate the safety and effectiveness of injecting MSCs into the heart to repair and restore heart function in people who have had a heart attack and who are having heart surgery for coronary artery bypass grafting (CABG).


Options:
A: Arm Label: Lower dose mesenchymal stem cell (MSC) injection; Type: EXPERIMENTAL; Interventions: Biological: Lower dose mesenchymal stem cell (MSC) injection | Arm Label: Higher dose MSC injection; Type: EXPERIMENTAL; Interventions: Biological: Higher dose MSC injection | Arm Label: (3) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Genetic: Placebo | Intervention Type: BIOLOGICAL; Name: Lower dose mesenchymal stem cell (MSC) injection; Assigned to Arm(s): Lower dose mesenchymal stem cell (MSC) injection | Intervention Type: GENETIC; Name: Placebo; Assigned to Arm(s): (3) Placebo | Intervention Type: BIOLOGICAL; Name: Higher dose MSC injection; Assigned to Arm(s): Higher dose MSC injection
B: Arm Label: Intramyocardial injection of BM cells; Type: EXPERIMENTAL; Interventions: Other: intramyocardial injection of BM cells | Arm Label: Intramyocardial / intracoronary injection of BM cells; Type: EXPERIMENTAL; Interventions: Other: intramyocardial / intracoronary injection of BM cells | Arm Label: control; Type: OTHER; Interventions: Other: Best medical therapy | Intervention Type: OTHER; Name: intramyocardial injection of BM cells; Assigned to Arm(s): Intramyocardial injection of BM cells | Intervention Type: OTHER; Name: intramyocardial / intracoronary injection of BM cells; Assigned to Arm(s): Intramyocardial / intracoronary injection of BM cells | Intervention Type: OTHER; Name: Best medical therapy; Assigned to Arm(s): control
C: Intervention Type: PROCEDURE; Name: Bone Marrow Stem Cell Therapy combined CABG; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: intracoronary infusion of progenitor cells; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study
Brief Summary: One dose of either gabapentin or placebo will be given to patients prior to thoracotomy. Patients will also receive an epidural infusion, intravenous patient-controlled analgesia with fentanyl, oral acetaminophen and intravenous ketorolac as needed to achieve optimal analgesia. Pain ratings and supplemental medication use will be recorded for 48 hours and will also be assessed at 3 months postoperatively to determine whether the patients who received gabapentin had improved analgesia and/or required less supplemental medication than the placebo group.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin Complex (placebo) | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Vitamin Complex (placebo); Assigned to Arm(s): Placebo
B: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine
C: Arm Label: Gabapentin preoperatively; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Active placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diphenhydramine | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin preoperatively | Intervention Type: DRUG; Name: Diphenhydramine; Assigned to Arm(s): Active placebo
D: Intervention Type: DRUG; Name: morphine and mexiletine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects With Ventilator-Associated Pneumonia
Brief Summary: The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
B: Arm Label: Ceftobiprole medocaril; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole medocaril | Arm Label: IV standard-of-care cephalosporin; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV standard-of-care cephalosporin | Intervention Type: DRUG; Name: ceftobiprole medocaril; Assigned to Arm(s): Ceftobiprole medocaril | Intervention Type: DRUG; Name: IV standard-of-care cephalosporin; Assigned to Arm(s): IV standard-of-care cephalosporin
C: Arm Label: Colistin and Meropenem; Type: EXPERIMENTAL; Interventions: Drug: Colistin, Drug: Meropenem | Arm Label: Colistin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colistin | Intervention Type: DRUG; Name: Colistin; Assigned to Arm(s): Colistin, Colistin and Meropenem | Intervention Type: DRUG; Name: Meropenem; Assigned to Arm(s): Colistin and Meropenem
D: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects With Ventilator-Associated Pneumonia
Brief Summary: The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.


Options:
A: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: tigecycline | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: tigecycline | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: imipenem/cilastatin | Intervention Type: DRUG; Name: tigecycline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: tigecycline; Assigned to Arm(s): B | Intervention Type: DRUG; Name: imipenem/cilastatin; Assigned to Arm(s): C
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
D: Intervention Type: DRUG; Name: doripenem; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects With Ventilator-Associated Pneumonia
Brief Summary: The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
B: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Amikacin (BAY41-6551) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Amikacin (BAY41-6551) | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Amikacin (BAY41-6551); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Amikacin (BAY41-6551); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
D: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Brief Summary: The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas. The approach used an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (aglatimagene besadenovec, CAN-2409), followed by an antiherpetic prodrug, valacyclovir. CAN-2409 was injected into the resection bed after standard tumor surgery and valacyclovir pills were taken for 14 days. Standard radiation and chemotherapy were administered which have been shown to work cooperatively with CAN-2409 + prodrug to kill tumor cells. The hypothesis is that this combination therapy can be safely delivered and will lead to improvement in the clinical outcome for patients with newly diagnosed malignant gliomas, including glioblastoma multiforme (WHO grade IV) and anaplastic astrocytomas (WHO grade III).


Options:
A: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation therapy | Arm Label: Radiotherapy plus Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Radiotherapy plus Bevacizumab | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Radiotherapy
B: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Biological: CAN-2409, Drug: Valacyclovir, Drug: Temozolomide, Radiation: Radiation therapy | Intervention Type: BIOLOGICAL; Name: CAN-2409; Assigned to Arm(s): Single arm | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): Single arm | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Single arm | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Single arm
C: Arm Label: radiotherapy; Type: OTHER; Interventions: Radiation: radiation therapy | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): radiotherapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Conformal radiotherapy | Arm Label: 2; Type: OTHER; Interventions: Radiation: Conventional radiotherapy | Intervention Type: RADIATION; Name: Stereotactic Conformal radiotherapy; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia
Brief Summary: The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.


Options:
A: Arm Label: RISPERDAL CONSTA; Type: ACTIVE_COMPARATOR; Interventions: Drug: RISPERDAL CONSTA | Arm Label: R092670; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone palmitate | Intervention Type: DRUG; Name: RISPERDAL CONSTA; Assigned to Arm(s): RISPERDAL CONSTA | Intervention Type: DRUG; Name: Paliperidone palmitate; Assigned to Arm(s): R092670
B: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: BL - 1020 | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: BL - 1020 | Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: BL - 1020; Assigned to Arm(s): I | Intervention Type: DRUG; Name: BL - 1020; Assigned to Arm(s): II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): IV
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: IM risperidone | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral antipsychotic medication | Intervention Type: DRUG; Name: IM risperidone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: oral antipsychotic medication; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events
Brief Summary: The purpose of ZEST-LATE (Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events) trial is to assess the relationship between long-term clopidogrel use beyond 1 year and long-term rates of death or MI after DES implantation and to estimate the duration of dual antiplatelet therapy for preventing the late thrombotic events.


Options:
A: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Aspirin,Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
C: Arm Label: aspirin+placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: aspirin + placebo | Arm Label: aspirin+pregrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin + pregrel (Clopidogrel resinate) | Arm Label: Aspirin+Plavix; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin + plavix (Clopidogrel bisulfate) | Intervention Type: DRUG; Name: aspirin + pregrel (Clopidogrel resinate); Assigned to Arm(s): aspirin+pregrel | Intervention Type: DRUG; Name: aspirin + placebo; Assigned to Arm(s): aspirin+placebo | Intervention Type: DRUG; Name: aspirin + plavix (Clopidogrel bisulfate); Assigned to Arm(s): Aspirin+Plavix
D: Arm Label: 75mg Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 mg daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: water pill daily | Intervention Type: DRUG; Name: Clopidogrel 75 mg daily; Assigned to Arm(s): 75mg Clopidogrel | Intervention Type: DRUG; Name: water pill daily; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygous Cystic Fibrosis Patients
Brief Summary: The purpose of this research study is to test a new combination of medicines, Phenylbutyrate and Genistein, to determine if they could be used to treat cystic fibrosis (CF). The most common genetic mutation found in patients with CF is called Delta F508. Due to this mutation, there is a lack of salt (chloride) movement in your nose, sinuses, lungs, intestines, pancreas and sweat glands. This lack of movement causes the clinical manifestations of the disease.

Although Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases, Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. When used together, both drugs may be able to restore normal chloride and salt (water) movements in body organs and glands in people with CF.

We will be studying salt and water movement in the nose by a technique called nasal transepithelial potential difference (NPD).


Options:
A: Arm Label: VX-659/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-659/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-659/TEZ/IVA; Assigned to Arm(s): VX-659/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-659/TEZ/IVA TC
B: Arm Label: Phenylbutyrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium 4-Phenylbutyrate, Drug: Genistein (Unconjugated Isoflavones 100) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Genistein (Unconjugated Isoflavones 100), Drug: Placebo | Intervention Type: DRUG; Name: Sodium 4-Phenylbutyrate; Assigned to Arm(s): Phenylbutyrate | Intervention Type: DRUG; Name: Genistein (Unconjugated Isoflavones 100); Assigned to Arm(s): Phenylbutyrate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lumacaftor/Ivacaftor (LUM/IVA); Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor, Drug: Ivacaftor | Intervention Type: DRUG; Name: Lumacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA) | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA)
D: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Strategy to Reduce the Incidence of Post-Operative Delirium in Elderly Patients
Brief Summary: This research is being done to see what effects sedative drugs during surgery have on peoples' thinking processes after they wake up.


Options:
A: Arm Label: Deeper sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Deeper sedation | Arm Label: Moderate sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Moderate sedation | Intervention Type: DEVICE; Name: Deeper sedation; Assigned to Arm(s): Deeper sedation | Intervention Type: DEVICE; Name: Moderate sedation; Assigned to Arm(s): Moderate sedation
B: Arm Label: Ketamine (0.5 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (0.5 mg/kg) | Arm Label: Normal saline (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (placebo) | Arm Label: Ketamine (1 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (1 mg/kg) | Intervention Type: DRUG; Name: Ketamine (0.5 mg/kg); Assigned to Arm(s): Ketamine (0.5 mg/kg) | Intervention Type: DRUG; Name: Normal Saline (placebo); Assigned to Arm(s): Normal saline (placebo) | Intervention Type: DRUG; Name: Ketamine (1 mg/kg); Assigned to Arm(s): Ketamine (1 mg/kg)
C: Arm Label: Sugammadex; Type: EXPERIMENTAL; Interventions: Drug: Sugammadex | Arm Label: Neostigmine/glycopyrrolate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neostigmine, Drug: Glycopyrrolate | Intervention Type: DRUG; Name: Sugammadex; Assigned to Arm(s): Sugammadex | Intervention Type: DRUG; Name: Neostigmine; Assigned to Arm(s): Neostigmine/glycopyrrolate | Intervention Type: DRUG; Name: Glycopyrrolate; Assigned to Arm(s): Neostigmine/glycopyrrolate
D: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL

Answer: A